Previous studies from this laboratory have described the use of the rhesus monkey pretreated with vincristine sulfate (VCR) as a model for severe, often lethal Pseudomonas sepsis (11) . The results comparing tobramycin, gentamicin, carbenicillin, and colistin in this model have been reported (12) . It is the purpose of this report to compare the effects of the combination of colistin and carbenicillin in Pseudomonas sepsis.
MATERIALS AND METHODS Forty-two fully conditioned, young adult monkeys (Macaca mulatta) weighing 2.7 to 4.0 kg were used in the therapy studies. Base line observations included physical examinations and hematological and bacteriological studies for 2 weeks prior to intratracheal administration of 2.0 to 2.5 mg of VCR as previously described (11, 12) . Intravenous challenge with a pyocin type 6 strain of P. aeruginosa (Bricker strain) was conducted 5 days after VCR administration. The 6-hr Trypticase soy broth (BBL) cultures of the Pseudomonas used were prepared as previously described (11, 12) . Therapy with colistin, carbenicillin, and colistin and carbenicillin in combination was instituted 16 hr postchallenge and continued for 10 days. The daily dose was divided equally and given intramuscularly at 8:00 a.m. and 5:00 p.m. In monkeys receiving both agents, the antibiotics were given in separate syringes at opposite sites. Controls given VCR followed by Pseudomonas challenge received saline intramuscularly.
Monkeys were examined at least twice daily for 3 weeks after challenge with 6.2 x 1010 to 6.7 x 1010 organisms and daily thereafter for at least 2 months. Laboratory studies included blood counts, blood cultures, C-reactive protein (CRP) tests, and blood urea nitrogen (BUN) determinations, as previously described (12) . Autopsies were performed on all fatally infected monkeys.
Serum antibacterial activity (ABA) was determined by using the challenge Pseudomonas as the test organisms (5, 12) . In addition, ABA of serum from 24 normal monkeys given colistin and carbenicillin, singly and in combination, was studied. Six groups of four monkeys each were given single intramuscular doses of 1.25 or 0.63 mg of colistin per kg, 25 or 12.5 mg of carbenicillin per kg, 1.25 mg of colistin and 25 mg of carbenicillin per kg, and 0.63 mg of colistin and 12.5 mg of carbenicillin per kg. Blood samples were obtained before and 1, 2, 4, and 8 hr after dosing. nas challenge and on the day when therapy was instituted. Variation in clinical response to VCR was observed in the 42 monkeys in the three experiments combined. All 42 had mild anorexia on the date of Pseudomonas challenge (day 0), 12 of 42 exhibited mild diarrhea, and 8 of 12 were mildly lethargic when observed from a distance, but appeared active and alert when the cage was approached. In addition, variation in hematological response to VCR was noted in the 42 monkeys; 37 exhibited relative leukopenia on day 0, whereas 5 did not. In experiments 1, 2, and 3, 9 of 12, 11 of 12, and 17 of 18 monkeys, respectively, exhibited total leukocyte counts on day 0 which were less than half of the mean of at least two pre-VCR counts (Table 1 ). Decreases after administration of VCR affected both neutrophiles and lymphocytes, as previously noted (8, 11, 12) .
All 42 monkeys in the three experiments were moderately to acutely ill on the morning of the day after Pseudomonas challenge (day 1) when therapy was started. The clinical status of each monkey was evaluated independently by the three investigators, and the monkeys were then divided into apparently comparable groups. The antibiotic regimen to be used was then established by lot.
Studies on therapy of Pseudomonas infection. In experiment 1, 12 monkeys were inoculated intratracheally with 2.5 mg of VCR and challenged 5 days later with 6.2 x 1010 Pseudomonas cells ( Table 2) . Three of these monkeys were treated with 2.5 mg of colistin per kg per day, three received 50 mg of carbenicillin per kg per day, and three were treated with 2.5 mg of colistin in combination with 50 mg of carbenicillin per kg per day. The remaining three monkeys served as untreated controls.
All three controls were dead by the afternoon of day 2. Gross pathology was similar in the three monkeys; the lungs showed scattered areas of hemorrhage and congestion, the liver was pale, mottled, and slightly enlarged, and the spleen was dark in color and about twice normal size. Pseudomonas was isolated from heart blood and all major organs of all three monkeys. The three monkeys treated with colistin were acutely ill for 2 to 4 days; they then recovered rapidly and appeared normal after day 6. Blood cultures were positive only on day 3 in all three monkeys, and CRP tests were negative after day 10 in all three. The three monkeys given carbenicillin began to improve after 4 to 6 days of therapy, and all were fully recovered by day 9 . Positive blood cultures were obtained only on day 3 in all three monkeys, and CRP tests were positive for 10 days in two monkeys and for 14 days in one.
One (no. 99) of three monkeys treated with colistin and carbenicillin was extremely lethargic, weak, and anorectic during the first 4 days of therapy. Although some improvement was noted on day 5, it was still acutely ill and remained so through day 13. It became progressively worse beginning on day 14 and died on day 20. The gross pathology was not remarkable and was in no way indicative of the cause of death. None of the major organs or heart blood yielded Pseudomonas when cultured. On day 4, the skin of this monkey showed numerous clusters of macular lesions 1 mm or less in diameter. The lesions had coalesced by day 6 and a serous exudate was observed. Culture of this material revealed only normal skin flora. The patches began to darken on about day 8, and by day 11 they were coal-black in color and resembled ecthyma gangrenosum. Sloughing of the superficial layers beginning on day 14 revealed little or no involvement of the subcutaneous tissue. Subsequent healing was rapid, and the skin appeared almost normal when the monkey died on day 20. A positive blood culture was obtained on day 3, but all subsequent cultures were negative. CRP tests were strongly positive continuously up to death. The total leukocyte count (Table 1) on the day of challenge (5 days after VCR) was 3.8 as compared to the base line count of 15.3 per mm3. The total count was 42,400 per mm3 on day 6, 76,300 on day 10, and 43,900 per mm3 on day 14.
A second monkey (no. 101) treated with colistin and carbenicillin was acutely ill for only 3 days and appeared well after day 4. However, blood cultures were positive on days 3 to 17; CRP tests were positive for 14 days. Thus, this monkey exhibited positive blood cultures for about 2 weeks after it was apparently normal. The third monkey (no. 95) in the colistin-carbenicillin group was acutely ill for 4 days and was normal by day 7. Blood cultures were positive for 3 days and CRP tests were positive for 10 days.
In experiment 2 ( In experiment 3, the VCR dose was reduced to 2.0 mg, given intratracheally; antibiotic doses were the same as in experiment 2 after challenge with 6.7 x 1010 Pseudomonas cells.
Three of four controls were dead by the afternoon of day 2 ( Table 2) . Three of four, three of four, and three of six monkeys treated with colistin, carbenicillin, and colistin-carbenicillin, respectively, did not respond to therapy and died on days 2 to 3, days 3 to 5, and day 2, respectively. Heart blood and all major organs of all 12 monkeys yielded Pseudomonas when cultured.
Duration of illness in the six survivors is shown in Positive CRP was observed on days 3 and 6 in all of the 19 treated monkeys that survived. All except four of the survivors had negative CRP by day 17. The four exceptions had positive CRP through day 28; three (no. 134, 147, and 148) had received carbenicillin and colistin, and one (no. 128) had received carbenicillin.
The hematological response to VCR and to subsequent challenge with Pseudomonas is shown in Table 1 . A relative leukopenia was observed on day 0 (day 5 post-VCR) in 8 of 10, 8 of 10, and 11 of 12 monkeys treated with colistin, carbenicillin, and colistin plus carbenicillin, respectively; at this time, mean leukocyte counts in these monkeys were 3,650, 3,550, and 3,260 per mm ', respectively. Leukocyte counts were usually lower on day 1 than on day 0; the means in the leukopenic monkeys on day 1 were 2,310, 2,100, and 1,700 in the colistin, carbenicillin, and colistin-carbenicillin therapy groups, respectively. At this time, the mean leukocyte count in untreated controls was 1,480 per mm3.
Polymorphonuclear leukocytosis was observed on day 6 in most of the surviving monkeys; the means of the leukocyte counts at this time were 22,500, 29,730, and 30,100 per mm3 in monkeys treated with colistin, carbenicillin, and colistin plus carbenicillin, respectively, as compared to base line means of 13,250, 14,910, and 13,570 per mm3, respectively. The two surviving controls, who had base lines of 9,900 and 9,600 leukocytes per mm3, showed counts on day 6 of 27,500 and 38,800 per mm3, respectively. BUN determinations on day 2 showed transient increases in the two untreated survivors.
Increases from base lines of 13 and 21 mg/100 ml to 36 and 59 mg/100 ml were obtained in monkeys 116 and 138, respectively. All of 11 of the 14 treated monkeys that died, in which BUN determinations were performed, showed increases on day 2 from base lines of 13 to 23 mg/100 ml to values ranging from 34 to 147 mg/100 ml. Changes in BUN were less marked in the 18 treated monkeys that survived, except for two in the carbenicillintreated group (no. 87 and 128); BUN levels in these two monkeys were 133 and 109 mg/100 ml on day 2 but were back to normal on day 6, as were those of all the other surviving monkeys. Serum ABA of samples obtained 2 hr after the morning dose on days 2 and 9 were similar in all therapy groups. Minimal inhibitory concentrations of colistin and carbenicillin for the challenge Pseudomonas used in measuring serum ABA were 3.13 and 62.5 gg/ml, respectively. All monkeys given colistin showed ABA titers of 1:2, except for one (no. 108) which had a titer of 1:4. All except two monkeys receiving carbenicillin (no. 100 and 142), which died on day 3, showed ABA titers of 1: 2 on day 2. Among the monkeys receiving 25 mg of carbenicillin per kg per day, all except no. 64 had ABA titers of 1: 2. In monkeys receiving both agents, ABA titers of 1:2 to 1:4 were observed in all specimens tested.
Serum ABA titers in normal monkeys are shown in Table 3 (12) . The same variations in individual monkeys discussed in those experiments in reference to the effect of VCR, the hematological response, and the degree of azotemia occurred in this study. Although it is recognized that agranulocytosis is a predisposing factor in human Pseudomonas infections (1, 2, 4, 13) , the selection of monkeys into relatively comparable therapy groups on this basis was not attempted because blood counts done on the day of challenge were not completed until later in the day. Thus, selection of groups was made on a clinical basis. Despite this mode of selection, the therapy groups as a whole did not differ significantly in reference to leukopenia at the time of challenge (day 0); 2 of 10, 2 of 10, and 1 of 12 had total white counts of 2,000 or less per mm3 in the colistin, carbenicillin, and colistin-carbenicillin therapy groups, respectively. Survival was more closely related to ability to respond with a leukocytosis after challenge. For example, the six colistin-treated monkeys that died (no. 108, 11, 126, 115, 141, and 144) had total leukocyte counts of less than 2,000 per mm3 with total neutrophils varying from 200 (12) . One would be tempted to attribute survival in the latter group to the higher dose alone, but ABA was similar in all three therapy groups. However, since the monkeys in the 400 mg/kg dose group had received intratracheal VCR, the route of administration AND MOHEIMANI or antagonism could be shown.
As in previous studies (6, 7, 9, 10) , elevations in BUN were observed as a consequence of infection. No evidence on antibiotic-induced nephrotoxicity was observed in any of the therapy groups.
Under the conditions of this study, no significant therapeutic superiority of the combination of colistin and carbenicillin over the agents employed singly could be demonstrated. Similar observations in reference to gentamicin and carbenicillin have been made in this laboratory and will be reported separately.
